TITLE:
Boiogito Increases the Synthesis and Secretion of Adiponectin by Promoting Differentiation in Cultured Human Adipocytes
AUTHORS:
Yuan Gu, Ailing Hu, Takuji Yamaguchi, Masahiro Tabuchi, Yasushi Ikarashi, Hiroyuki Kobayashi
KEYWORDS:
Adipocyte, Adiponectin, Boiogito, Differentiation, Troglitazone
JOURNAL NAME:
Health,
Vol.15 No.12,
December
21,
2023
ABSTRACT: Boiogito
(BOT) ameliorates insulin resistance and diabetes in several animal models;
however, the underlying mechanisms for these in vivo effects remain unclear. Thiazolidine derivatives, which are
peroxisome proliferator-activated receptor γ (PPARγ) agonists for the treatment of
type II diabetes, promote adiponectin production by inducing adipocyte
differentiation, thereby reducing insulin resistance. This study aimed
to evaluate the effect of BOT on adipocyte
differentiation using cultured human visceral preadipocytes (HVPAds) compared with the thiazolidine derivative
troglitazone (TRG). We investigated the effects of BOT (0.125 - 1 mg/mL)
and TRG (10 μM) on the differentiation of
adipocytes treated with or without tumor necrosis factor-α (TNF-α: 5 ng/mL). On
day 14 of culture, the following adipocyte differentiation marker levels were measured: intracellular lipids,
extracellular (i.e., medium) adiponectin,
and intracellular differentiation-related genes (PPARγ, CCAAT/enhancer binding
protein, adiponectin, differentiation cluster 36, glucose transporter
type 4). BOT and TRG increased factors associated with differentiation
including lipid, adiponectin, and differentiation-related gene expression
levels compared with the controls. The increases in these differentiation
markers were inhibited by the PPARγ antagonist GW9662 (20 μM). Furthermore, TNF-α decreased all differentiation marker levels. The decreases in differentiation
markers were inhibited by BOT and TRG; however, these inhibitory effects were
blocked by GW9662. The results suggest that BOT increases the synthesis and
secretion of adiponectin by promoting differentiation similar to TRG. This
study is the first to demonstrate that adipocyte differentiation-promoting
activity is a mechanism for the beneficial effects of BOT on diabetes and
insulin resistance.